{"id":64501,"date":"2024-09-28T12:04:52","date_gmt":"2024-09-28T12:04:52","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=64501"},"modified":"2026-04-30T10:23:29","modified_gmt":"2026-04-30T10:23:29","slug":"bupcart-xl-150","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/bupcart-xl-150\/","title":{"rendered":"Bupcart-XL 150"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Bupcart-XL 150 (Bupropion 150 mg, extended-release (XL)) is a dopamine-noradrenaline reuptake inhibitor (NDRI) used for major depression, smoking cessation (Zyban indication), and seasonal affective disorder. Distinct profile: stimulating rather than sedating, weight-neutral or weight-reducing, no sexual side effects. XL is once-daily \u2014 better adherence than the BID SR formulation.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Bupcart-XL 150 at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

What Bupcart-XL 150 is and how it works<\/h2>\n

Bupcart-XL 150 is a 150 mg bupropion extended-release (XL) tablet supplied by Cardinal Healthcare. Bupropion is the only widely-prescribed antidepressant whose primary action is dopamine-noradrenaline reuptake inhibition \u2014 not serotonin reuptake. This makes it pharmacologically distinct from SSRIs\/SNRIs\/TCAs and explains its different side-effect signature.<\/p>\n

Klinick\u00fd p\u0159eklad: bupropion nezp\u016fsobuje sexu\u00e1ln\u00ed dysfunkci, nevede k p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze (\u010dasto naopak k \u00fabytku) a m\u00e1 sp\u00ed\u0161e aktiva\u010dn\u00ed ne\u017e sedativn\u00ed \u00fa\u010dinky. Nev\u00fdhodou je v\u00fdznamn\u011b zv\u00fd\u0161en\u00e9 riziko z\u00e1chvat\u016f p\u0159i vysok\u00fdch d\u00e1vk\u00e1ch, absolutn\u00ed kontraindikace u poruch p\u0159\u00edjmu potravy a u n\u011bkter\u00fdch pacient\u016f m\u016f\u017ee vyvolat nespavost\/\u00fazkost.<\/p>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n
Indikace<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Hlavn\u00ed deprese \u2014 XL<\/td>\n150 mg 1\u00d7 denn\u011b r\u00e1no<\/td>\n300 mg 1\u00d7 denn\u011b<\/td>\n450 mg<\/td>\n<\/tr>\n
Hlavn\u00ed deprese \u2014 SR<\/td>\n150 mg 1\u00d7 denn\u011b po dobu 3 dn\u016f \u2192 2\u00d7 denn\u011b<\/td>\n150 mg 2\u00d7 denn\u011b<\/td>\n200 mg 2\u00d7 denn\u011b<\/td>\n<\/tr>\n
Odvyk\u00e1n\u00ed kou\u0159en\u00ed<\/td>\n150 mg 1\u00d7 denn\u011b po dobu 3 dn\u016f \u2192 2\u00d7 denn\u011b (SR) nebo 150 mg 1\u00d7 denn\u011b po dobu 1 t\u00fddne \u2192 300 mg (XL)<\/td>\n150 mg 2\u00d7 denn\u011b nebo 300 mg 1\u00d7 denn\u011b po dobu 7\u201312 t\u00fddn\u016f<\/td>\n\u2014<\/td>\n<\/tr>\n
Sez\u00f3nn\u00ed afektivn\u00ed porucha (XL)<\/td>\n150 mg 1\u00d7 denn\u011b, za\u010d\u00e1tek na podzim<\/td>\n300 mg 1\u00d7 denn\u011b<\/td>\n\u2014<\/td>\n<\/tr>\n
SSRI sexu\u00e1ln\u00ed dysfunkce (mimo indikaci)<\/td>\n75\u2013150 mg 1\u00d7 denn\u011b<\/td>\n150 mg 1\u00d7 denn\u011b<\/td>\n300 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nRiziko z\u00e1chvat\u016f \u2014 absolutn\u00ed a d\u00e1vkov\u011b z\u00e1visl\u00e9<\/strong><\/p>\n

Bupropion sni\u017euje pr\u00e1h pro z\u00e1chvaty. Absolutn\u00ed kontraindikace:<\/strong> jak\u00e1koli z\u00e1chvatov\u00e1 porucha, sou\u010dasn\u00e1 nebo anamn\u00e9za ment\u00e1ln\u00ed anorexie nebo bulimie, n\u00e1hl\u00e9 vysazen\u00ed alkoholu nebo sedativ. Riziko z\u00e1chvat\u016f p\u0159i 300 mg\/den je p\u0159ibli\u017en\u011b 0,1 %; p\u0159i 450 mg\/den je p\u0159ibli\u017en\u011b 0,4 % \u2014 \u010dty\u0159n\u00e1sobn\u00fd n\u00e1r\u016fst. Jednotliv\u00e9 d\u00e1vky nesm\u00ed p\u0159ekro\u010dit 150 mg (SR) nebo 450 mg celkem (XL).<\/p>\n<\/div>\n

\nKontraindikace u poruch p\u0159\u00edjmu potravy<\/strong><\/p>\n

Anorexie a bulimie jsou absolutn\u00ed kontraindikace \u2014 jak proto, \u017ee fyziologie poruch p\u0159\u00edjmu potravy sni\u017euje pr\u00e1h pro z\u00e1chvaty (elektrolytov\u00e1 nerovnov\u00e1ha, ketotick\u00fd stav), tak proto, \u017ee anorektick\u00fd \u00fa\u010dinek bupropionu m\u016f\u017ee upev\u0148ovat restriktivn\u00ed chov\u00e1n\u00ed. Toto je jedna z m\u00e1la jasn\u00fdch \u201cnepou\u017e\u00edvat\u201d situac\u00ed v psychiatrii.<\/p>\n<\/div>\n

\nVylou\u010den\u00ed MAOI<\/strong><\/p>\n

14denn\u00ed vylou\u010den\u00ed v obou sm\u011brech. Sou\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed riskuje hypertenzn\u00ed krizi.<\/p>\n<\/div>\n

\n\u010cern\u00e9 varov\u00e1n\u00ed ohledn\u011b sebevra\u017eednosti (u osob do 25 let)<\/strong><\/p>\n

V\u0161echna antidepresiva nesou \u010dern\u00e9 varov\u00e1n\u00ed FDA ohledn\u011b zv\u00fd\u0161en\u00e9ho rizika sebevra\u017eedn\u00fdch my\u0161lenek u pacient\u016f mlad\u0161\u00edch 25 let.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n